1. Home
  2. MC vs CRSP Comparison

MC vs CRSP Comparison

Compare MC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moelis & Company

MC

Moelis & Company

HOLD

Current Price

$65.86

Market Cap

4.9B

Sector

Finance

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$47.19

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MC
CRSP
Founded
2007
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.0B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
MC
CRSP
Price
$65.86
$47.19
Analyst Decision
Buy
Buy
Analyst Count
8
17
Target Price
$72.88
$70.29
AVG Volume (30 Days)
891.6K
1.6M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
3.88%
N/A
EPS Growth
N/A
N/A
EPS
0.75
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
$18.28
$807.72
Revenue Next Year
$17.22
$172.52
P/E Ratio
$90.46
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$51.06
$44.12
52 Week High
$78.22
$78.48

Technical Indicators

Market Signals
Indicator
MC
CRSP
Relative Strength Index (RSI) 48.15 37.08
Support Level $61.71 N/A
Resistance Level $71.87 $59.61
Average True Range (ATR) 2.61 2.98
MACD 0.02 -1.07
Stochastic Oscillator 35.65 2.69

Price Performance

Historical Comparison
MC
CRSP

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: